Evaluation of non-exudative microcystoid macular abnormalities secondary to retinal vein occlusion

• Published in: Graefe's archive for clinical and experimental ophthalmology Vol. 259; no. 12; pp. 3579 - 3588
• Main Authors: Francone, Anibal, Govetto, Andrea, Yun, Lisa, Essilfie, Juliet, Nouri-Mahdavi, Kouros, Sarraf, David, Hubschman, Jean-Pierre
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.12.2021; Springer Nature B.V
• Subjects: Acuity; Angiogenesis Inhibitors - therapeutic use; Eye; Follow-Up Studies; Glaucoma; Humans; Intravitreal Injections; Macular Edema - drug therapy; Medical records; Medicine; Medicine & Public Health; Occlusion; Ophthalmology; Optic neuropathy; Patients; Retina; Retinal Disorders; Retinal Vein Occlusion - complications; Retinal Vein Occlusion - diagnosis; Retinal Vein Occlusion - drug therapy; Tomography, Optical Coherence; Treatment Outcome; Vascular endothelial growth factor; Visual Acuity; Retinal vein occlusion; Glaucoma; Central retinal vein occlusion; Microcysts; Optic neuropathy; Optical coherence tomography; Microcystoid macular abnormalities; Inner nuclear layer; Microcystoid macular changes; Microcystoid degeneration; Branch retinal vein occlusion
• ISSN: 0721-832X; 1435-702X
• DOI: 10.1007/s00417-021-05250-9

Purpose We aimed to investigate non-exudative microcystoid macular abnormalities for visual and anatomical outcome in patients with retinal vein occlusion (RVO) with and without glaucomatous optic neuropathy (GON). Methods Medical records of 124 eyes (105 patients) with RVO were reviewed and analyzed. Eyes demonstrating microcystoid macular abnormalities were divided into 2 groups, those with evidence of glaucoma (group A) and those without glaucoma (group B). Best-corrected visual acuity (BCVA), the prevalence and number of microcystoid macular abnormalities, and number of intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections were compared at baseline and follow-up. Results Seventy-one out of 105 eyes (67.6%) with RVO displayed microcystoid macular abnormalities. Thirty-eight out of 71 eyes (53.5%) presented with concomitant glaucoma (group A), while the remaining 33 eyes (42.6%) had no history of glaucoma (group B). At the end of the follow-up period, mean BCVA was worse in group A versus group B (20/80 versus 20/40, respectively; p = .003). The mean number of anti-VEGF injections was 10.1 ± 9.2 in group A versus 5.9 ± 6.9 in group B (p = .03). Conclusion Eyes with RVO and concomitant glaucoma exhibited a significantly higher number of microcystoid macular abnormalities and worse BCVA versus eyes with RVO without glaucoma.